$IMUX Immunic Inc. Falls 73% Following Pre-Planned Phase 1b Interim Analysis of IMU-935
Attaching this chart to this tweet $TRVN
1
2
$MCRB Analyst is delusional...
Seres Therapeutics PT Raised to 'Street High' $30 at Oppenheimer
2
$MCRB After vanco and dificid, there's no other effective C diff treatment so this is very needed
$MCRB Seres Therapeutics Climbs 180% Following Positive Topline Results from SER-109 Phase 3 ECOSPOR III Study in Recurrent C. difficile Infection


